Antibody Approaches To Treat Brain Diseases

详细信息    查看全文

• 作者：Vera Neves¹ ; ^{veraneves@medicina.ulisboa.pt" class="auth_mail" title="E-mail the corresponding author} ; Frederico Aires-da-Silva² ; ^{fasilva@fmv.ulisboa.pt" class="auth_mail" title="E-mail the corresponding author} ; Sofia Corte-Real³ ; Miguel A.R.B. Castanho¹
• 关键词：blood&ndash ; brain barrier ; central nervous system disorders ; brain drug delivery ; recombinant antibodies ; bispecific antibodies ; molecular Trojan horses (MTH)
• 刊名：Trends in Biotechnology
• 出版年：2016
• 出版时间：January 2016
• 年：2016
• 卷：34
• 期：1
• 页码：36-48
• 全文大小：2262 K

文摘

Recombinant antibodies are an emerging class of therapeutics with substantial promise to treat central nervous system (CNS) diseases such as Alzheimer's, Parkinson's, stroke, and brain cancers. However, poor blood–brain barrier (BBB) permeability hinders the progress of antibody therapies for conditions in which the target is located in the brain. Nonetheless, antibodies can nowadays be engineered to enhance their therapeutic applications and translocation of the BBB using the natural portals of the brain. This paper reviews advances in the development and engineering of therapeutic BBB-crossing antibodies and their high potential for treatment of CNS disorders.